Alloy Therapeutics is rewriting how biotech thinks about IP


Alloy Therapeutics recently launched what it calls an "Innovation Subscription," an annual-fee-based, tiered service that allows pharma companies to "subscribe" to the internal workings of Alloy.

Previous TriHealth launches record $30M fundraising campaign to support $240M project at Good Samaritan
Next PhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $100M